ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

NWCI Newcardio Inc (CE)

0.000001
0.00 (0.00%)
31 Jan 2025 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Newcardio Inc (CE) USOTC:NWCI OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.000001 0.000001 0.000001 0.000001 1,300 00:00:00

NewCardio to Participate in Benchmark Company, LLC 2011 One-on-One Investor Conference

18/04/2011 1:48pm

PR Newswire (US)


Newcardio (CE) (USOTC:NWCI)
Historical Stock Chart


From Feb 2020 to Feb 2025

Click Here for more Newcardio (CE) Charts.

SANTA CLARA, Calif., April 18, 2011 /PRNewswire/ -- NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic technology provider, announced today that Vincent Renz, President and Chief Executive Officer, will participate in the Benchmark Company, LLC One-on-One Investor Conference on Thursday, May 12, 2011 at The Pfister Hotel, 424 East Wisconsin Ave., Milwaukee, Wis. The conference will include a number of one-on-one meetings arranged by Benchmark with investors. Investors planning to attend the conference should contact their Benchmark representative to arrange a meeting.

About The Benchmark Company, LLC

Headquartered in New York City, The Benchmark Company, LLC is an institutional brokerage firm with a strong sales/trading presence in addition to its rapidly expanding research and investment banking arms. In just nine years, Benchmark has established offices in 12 cities throughout the country.

About NewCardio, Inc.

NewCardio is a cardiac diagnostic and services company developing and marketing proprietary software platform technologies to provide higher accuracy to, and increase the value of, the standard 12L ECG. NewCardio's 3-D ECG software platform reduces the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. NewCardio's software products and services significantly improve the diagnosis and monitoring of cardiovascular disease, as well as cardiac safety assessment of drugs under development. For more information, visit www.newcardio.com.

To join our email distribution please click this link: http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0

Investor Contact:

Hayden IR

Jeff Stanlis, Partner

(602) 476-1821

jeff@haydenir.com

SOURCE NewCardio, Inc.

Copyright 2011 PR Newswire

1 Year Newcardio (CE) Chart

1 Year Newcardio (CE) Chart

1 Month Newcardio (CE) Chart

1 Month Newcardio (CE) Chart

Your Recent History

Delayed Upgrade Clock